Advanced search
Publication Cover
International Medical Case Reports Journal Volume 14, 2021 - Issue
Submit an article Journal homepage
144
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin

Alexa ThibodeauDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USAORCID Iconhttps://orcid.org/0000-0002-5533-5399
ORCID Icon &
Nambi NallasamyDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7501-7198
ORCID Icon
Pages 707-709 | Published online: 01 Oct 2021

References

  • Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221–e1234.
  • Gupta VB, Rajagopala M, Ravishankar B. Etiopathogenesis of cataract: an appraisal. Indian J Ophthalmol. 2014;62(2):103–110. doi:10.4103/0301-4738.121141
  • A Study of Enfortumab Vedotin alone or with other therapies for treatment of urothelial cancer (EV-103). NIH: U.S. National Library of Medicine. ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03288545?term=EV-103&draw=2&rank=1. Accessed June 25, 2021.
  • Chang E, Weinstock C, Zhang L, et al. FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2020. doi:10.1158/1078-0432.ccr-20-2275
  • Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592–2600. doi:10.1200/JCO.19.01140
  • PADCEV (enfortumab vedotin-ejfv) [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2019.
  • Viscuse PV, Marques-Piubelli ML, Heberton MM, et al. Case report: enfortumab vedotin for metastatic urothelial carcinoma: a case series on the clinical and histopathologic spectrum of adverse cutaneous reactions from Fatal Stevens-Johnson Syndrome/toxic epidermal necrolysis to dermal hypersensitivity reaction. Front Oncol. 2021;11:621591.
  • Sasaki R, Fujimura T, Lyu C, Aiba S. Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin. J Dermatol. 2020;47(12):1436–1438. doi:10.1111/1346-8138.15577
  • Dobry AS, Virgen CA, Hosking AM, et al. Cutaneous reactions with enfortumab vedotin: a case series and review of the literature. JAAD Case Rep. 2021;14:7–9. doi:10.1016/j.jdcr.2021.05.020
  • Francis A, Jimenez A, Sundaresan S, Kelly B. A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis. JAAD Case Rep. 2021;7:57–59. doi:10.1016/j.jdcr.2020.10.020
  • Bowling B. Kanski’s Clinical Ophthalmology: A Systematic Approach. 8th ed. Elsevier; 2016.
  • de Iongh RU, Wederell E, Lovicu FJ, McAvoy JW. Transforming growth factor-beta-induced epithelial-mesenchymal transition in the lens: a model for cataract formation. Cells Tissues Organs. 2005;179(1–2):43–55. doi:10.1159/000084508
  • Lachke SA, Higgins AW, Inagaki M, et al. The cell adhesion gene PVRL3 is associated with congenital ocular defects. Hum Genet. 2012;131(2):235–250. doi:10.1007/s00439-011-1064-z

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.